Region Nordjylland
- Address
- Moelleparkvej 10, 9000 Aalborg, Denmark
Region Nordjylland - Multidisciplinary Clinical Research Center
Region Nordjylland is a comprehensive clinical research institution conducting advanced studies across multiple therapeutic domains. The center demonstrates particular expertise in nephrology and renal disease management, including investigations into blood infections in hemodialysis patients and membranous nephropathy, as well as significant contributions to oncology research with a focus on gastrointestinal and head-neck malignancies.
- Renal disease and dialysis-related complications, including infection prevention and proteinuria management
- Gastrointestinal oncology with emphasis on rectal cancer treatment strategies and post-surgical quality of life
- Head and neck squamous cell carcinoma with hypoxia-targeted radiotherapy approaches
- Dual diagnosis psychiatry investigating novel therapeutic interventions for co-occurring substance use disorders
The center's research portfolio reflects a patient-centered approach, addressing both acute clinical challenges and long-term quality of life outcomes. Notable investigations include antibiotic prophylaxis protocols for hemodialysis patients with central venous catheters, innovative neoadjuvant chemotherapy strategies for locally advanced rectal cancer, and management of low anterior resection syndrome. The center also explores emerging psychiatric treatments, including the application of metabolic medications for dual diagnosis patients with schizophrenia and alcohol use disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Region Midtjylland1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Midtjylland3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Nordjylland
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amiloride Hydrochloride | 1 | Unknown | 2026-06-30 | 2026-06-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.